| 產(chǎn)品編號(hào) | BIO0151SM |
| 英文名稱 | Anti-human DLL4 (Navicixizumab Biosimilar) |
| 中文名稱 | |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.17 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG2SA |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Immobilized human VEGF165 His at 2 ug/mL can bind Anti-DLL4 Reference Antibody (navicixizumab), EC50=0.01191 ug/mL.
The purity of Anti-DLL4 Reference Antibody (navicixizumab) is more than 95%, determined by SEC-HPLC.
Anti-DLL4 Reference Antibody (navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
